Cancer is a known risk of lentiviral-based gene therapies. Though bluebird says its gene therapy is engineered to avoid that risk, the company is suspending two clinical trials pending the outcome of its inquiry.
MedCity News
How to lead a digital transformation in healthcare sales [live webinar]
Join our live webinar with top MedTech sales experts to learn how to succeed in the digital revolution of medical device and healthcare sales.
Shares0
Remote selling – once thought to be a temporary adjustment, is now looking like a long-haul strategy. The pandemic has changed buyer behavior and created the need to adapt your sales strategy
quickly.
Moreover, as MedTech and healthcare sales are traditionally high-touch and in-person, there’s a lot of adjusting to do.
Bloobirds is a sales empowerment platform built for inside (and remote) sales teams ideal for healthcare companies. They’ve teamed up with sales leaders Martin Osborn of Medtronic and Steffen Haerterich of GE Healthcare for a live panel discussion.
MedCity News
Lawyers address what we can do and what we must do in vaccine rollout
Hospital counsel, state advisors, congregate care advocates and university leaders believe that public health ethics must drive the next steps in vaccine distribution and not the constraints of the law.
Shares1
A host of legal experts advised their peers to be guided by ethics, not the constraints of the law, in this next wave of vaccine distribution, in a timely presentation titled “Legal Issues in Covid-19 Distribution” webcast to viewers across the country.
In a myth-busting and wide-ranging two-and-a-half hour discussion sponsored by the New York City Bar, health law experts from academia, government, health care institutions and nonprofit advocacy groups representing vulnerable populations explored the potential legal limits on an equitable vaccine rollout, concluding we need to remain creative and listen to the most impacted stakeholders as we fight this pandemic.
MedCity News
GSK commits $345M to Vir as alliance expands to flu, other respiratory viruses
The amended pact follows a collaboration begun last year when GlaxoSmithKline paid Vir Biotechnology $250 million to team up on potential treatments for Covid-19. The expansion includes an influenza treatment based on Vir s antibody technology.
Shares0
GlaxoSmithKline’s coronavirus collaboration with Vir Biotechnology has yet to advance a product to the market but the progress thus far has convinced the pharmaceutical giant to broaden the partnership beyond Covid-19.
GSK is paying Vir $225 million up front and making a $120 million equity investment in its partner. The most advanced product candidate covered by the expanded agreement is VIR2482, a Vir influenza treatment in early-stage clinical development.
Insurer participation in the ACA individual marketplace is on the rise and the trend is driven by policy changes at the federal level and the lingering effects of the Covid-19 pandemic.